Overview
- Thorne and Procter & Gamble signed a definitive agreement on Aug. 4 for P&G to acquire Thorne, with CEO Shailesh Jejurikar citing a $3.8 billion price.
- The transaction is expected to close later this year and remains subject to customary closing conditions and regulatory approvals.
- L Catterton will sell Thorne after taking the company private for $680 million in 2023, a sale that represents roughly a 5.6 times multiple on that investment.
- Thorne has rapidly grown revenue, surpassing $500 million in 2025 and being reported on track for about $650 million in 2026, and it operates in-house manufacturing and strong practitioner and athlete partnerships.
- The acquisition expands P&G’s premium wellness lineup alongside brands like New Chapter, Metamucil and Align and signals continued strategic interest in personalized nutrition and preventive health from major consumer goods firms.